Sugi Predict

Sugi Predict / Compounds / SCHEMBL5250240

SCHEMBL5250240

SCHEMBL5250240

CCOC(=O)CN1CCCc2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 4/20 0.60
▸ CHRM4 P08173 4/20 0.60
▸ CHRM1 P11229 4/20 0.60
▸ CHRM3 P20309 4/20 0.60
▸ ALDH1A1 P00352 9/20 0.59
▸ GAA P10253 1/20 0.59
▸ NOTUM Q6P988 1/20 0.55
▸ MAPT P10636 5/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ ALPL P05186 1/20 0.52
▸ ALPG P10696 1/20 0.52
▸ KDM4E B2RXH2 3/20 0.51
▸ HPGD P15428 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ CASP1 P29466 1/20 0.51
▸ CASP7 P55210 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5660336 0.92 NOTUM (0.61) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL20340248 0.91 ALDH1A1 (0.59) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL1395834 0.86 CHRM2 (0.58) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL21331595 0.86 CHRM2 (0.62) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL5859908 0.86 ALDH1A1 (0.66) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL5940212 0.84 NOTUM (0.57) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL5940371 0.83 NOTUM (0.56) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL9979483 0.83 CHRM2 (0.54) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL2260669 0.83 CHRM2 (0.56) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL6232687 0.82 NOTUM (0.43) CHRM2CHRM4CHRM1CHRM3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116969981-A Dihydroquinoline compound and preparation method, pharmaceutical composition and application thereof 中国药科大学 2023-10-31 — — CN disclosed
US-10689504-B2 Two part curable composition Henkel IP & Holding GmbH (DE) 2020-06-23 — — US disclosed
US-20190023872-A1 TWO PART CURABLE COMPOSITION HENKEL AG & CO. KGAA (DE) 2019-01-24 — — US disclosed
US-9969690-B2 Cure accelerators for anaerobic curable compositions Henkel IP & Holding GmbH (DE) 2018-05-15 — — US disclosed
WO-2017172270-A1 TWO PART CURABLE COMPOSITIONS Henkel IP & Holding GmbH (DE) 2017-10-05 — — WO disclosed
US-20170174630-A1 CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS HENKEL AG & CO. KGAA (DE) 2017-06-22 — — US disclosed
US-20170174630-A1 CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS HENKEL AG & CO. KGAA (DE) 2017-06-22 — — US disclosed
EP-2809668-B1 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2017-04-12 — — EP disclosed
WO-2016054124-A1 CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS Henkel IP & Holding GmbH (DE) 2016-04-07 — — WO disclosed
US-9266876-B2 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2016-02-23 — — US disclosed
US-20140371204-A1 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2014-12-18 — — US disclosed
EP-2809668-A1 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2014-12-10 — — EP disclosed
WO-2013114332-A1 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-08 — — WO disclosed
EP-1260512-B1 NOVEL CYCLIC AMIDE DERIVATIVES MITSUBISHI PHARMA CORP (JP) 2007-07-04 — — EP disclosed
US-7166617-B2 Cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-01-23 — — US disclosed
US-20030212094-A1 Novel cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2003-11-13 — — US disclosed
WO-2003006022-A1 TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S LABORATORIES LTD. (IN) 2003-01-23 — — WO disclosed
EP-1260512-A1 NOVEL CYCLIC AMIDE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2002-11-27 — — EP disclosed
US-5977118-A 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones and compositions and methods of use thereof SANOFI (FR) 1999-11-02 — — US disclosed
US-5656629-A CYCLIC GUANOSINE MONOPHSPHATE-PHOSPHODIESTERASE INHIBITOR; USEFUL FOR TREATING HEART FAILURE AND/OR HYPERTENSION SANOFI WINTHROP, INC. (US) 1997-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174630-A1 CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS AHCY, AHCYL1, CAPG CHRM2 1516/4885CHRM4 1738/4885CHRM1 1406/4885
US-20030212094-A1 Novel cyclic amide derivatives SIGMAR1, OPRM1, OPRD1 CHRM2 114/4885CHRM4 116/4885CHRM1 66/4885
US-20140371204-A1 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives CXCR3, CXCR1, CXCR2 CHRM2 213/4885CHRM4 207/4885CHRM1 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.